vs
Amneal Pharmaceuticals, Inc.（AMRX）与Rackspace Technology, Inc.（RXT）财务数据对比。点击上方公司名可切换其他公司
Amneal Pharmaceuticals, Inc.的季度营收约是Rackspace Technology, Inc.的1.2倍（$814.3M vs $682.8M），Amneal Pharmaceuticals, Inc.净利率更高（4.3% vs -4.8%，领先9.1%），Amneal Pharmaceuticals, Inc.同比增速更快（11.5% vs -0.4%），Amneal Pharmaceuticals, Inc.自由现金流更多（$108.5M vs $56.0M），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（11.1% vs -0.6%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Rackspace Technology, Inc.是总部位于美国得克萨斯州圣安东尼奥的云计算企业，在弗吉尼亚州雷斯顿以及澳大利亚、加拿大、英国、印度、迪拜、瑞士、荷兰、德国、新加坡、墨西哥、中国香港等多个国家和地区设有办事处，数据中心分布于全球多个主要城市，为客户提供专业的云计算相关服务。
AMRX vs RXT — 直观对比
营收规模更大
AMRX
是对方的1.2倍
$682.8M
营收增速更快
AMRX
高出11.9%
-0.4%
净利率更高
AMRX
高出9.1%
-4.8%
自由现金流更多
AMRX
多$52.5M
$56.0M
两年增速更快
AMRX
近两年复合增速
-0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $682.8M |
| 净利润 | $35.1M | $-32.7M |
| 毛利率 | 36.5% | 17.6% |
| 营业利润率 | 13.8% | -0.5% |
| 净利率 | 4.3% | -4.8% |
| 营收同比 | 11.5% | -0.4% |
| 净利润同比 | 212.9% | 41.6% |
| 每股收益（稀释后） | $0.10 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXRXT
| Q4 25 | $814.3M | $682.8M | ||
| Q3 25 | $784.5M | $671.2M | ||
| Q2 25 | $724.5M | $666.3M | ||
| Q1 25 | $695.4M | $665.4M | ||
| Q4 24 | $730.5M | $685.6M | ||
| Q3 24 | $702.5M | $675.8M | ||
| Q2 24 | $701.8M | $684.9M | ||
| Q1 24 | $659.2M | $690.8M |
净利润AMRXRXT
| Q4 25 | $35.1M | $-32.7M | ||
| Q3 25 | $2.4M | $-67.1M | ||
| Q2 25 | $22.4M | $-54.5M | ||
| Q1 25 | $12.2M | $-71.5M | ||
| Q4 24 | $-31.1M | $-56.0M | ||
| Q3 24 | $-156.0K | $-186.6M | ||
| Q2 24 | $6.0M | $25.0M | ||
| Q1 24 | $-91.6M | $-640.6M |
毛利率AMRXRXT
| Q4 25 | 36.5% | 17.6% | ||
| Q3 25 | 34.9% | 19.4% | ||
| Q2 25 | 39.5% | 19.4% | ||
| Q1 25 | 36.8% | 19.1% | ||
| Q4 24 | 36.0% | 19.2% | ||
| Q3 24 | 38.4% | 20.3% | ||
| Q2 24 | 35.6% | 19.2% | ||
| Q1 24 | 36.1% | 19.2% |
营业利润率AMRXRXT
| Q4 25 | 13.8% | -0.5% | ||
| Q3 25 | 9.0% | -5.1% | ||
| Q2 25 | 15.4% | -3.8% | ||
| Q1 25 | 14.4% | -5.8% | ||
| Q4 24 | 10.4% | -4.2% | ||
| Q3 24 | 12.6% | -25.7% | ||
| Q2 24 | 13.6% | -7.9% | ||
| Q1 24 | -1.6% | -94.5% |
净利率AMRXRXT
| Q4 25 | 4.3% | -4.8% | ||
| Q3 25 | 0.3% | -10.0% | ||
| Q2 25 | 3.1% | -8.2% | ||
| Q1 25 | 1.8% | -10.7% | ||
| Q4 24 | -4.3% | -8.2% | ||
| Q3 24 | -0.0% | -27.6% | ||
| Q2 24 | 0.9% | 3.7% | ||
| Q1 24 | -13.9% | -92.7% |
每股收益（稀释后）AMRXRXT
| Q4 25 | $0.10 | $-0.13 | ||
| Q3 25 | $0.01 | $-0.28 | ||
| Q2 25 | $0.07 | $-0.23 | ||
| Q1 25 | $0.04 | $-0.31 | ||
| Q4 24 | $-0.10 | $-0.20 | ||
| Q3 24 | $0.00 | $-0.82 | ||
| Q2 24 | $0.02 | $0.11 | ||
| Q1 24 | $-0.30 | $-2.91 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $105.8M |
| 总债务越低越好 | $2.6B | $2.7B |
| 股东权益账面价值 | $-70.8M | $-1.2B |
| 总资产 | $3.7B | $2.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXRXT
| Q4 25 | $282.0M | $105.8M | ||
| Q3 25 | $201.2M | $99.5M | ||
| Q2 25 | $71.5M | $103.9M | ||
| Q1 25 | $59.2M | $128.0M | ||
| Q4 24 | $110.6M | $144.0M | ||
| Q3 24 | $74.0M | $157.1M | ||
| Q2 24 | $43.8M | $190.2M | ||
| Q1 24 | $46.5M | $282.6M |
总债务AMRXRXT
| Q4 25 | $2.6B | $2.7B | ||
| Q3 25 | $2.6B | $2.8B | ||
| Q2 25 | $2.2B | $2.8B | ||
| Q1 25 | $2.2B | $2.8B | ||
| Q4 24 | $2.4B | $2.8B | ||
| Q3 24 | $2.4B | $2.8B | ||
| Q2 24 | $2.4B | $2.9B | ||
| Q1 24 | $2.4B | $3.0B |
股东权益AMRXRXT
| Q4 25 | $-70.8M | $-1.2B | ||
| Q3 25 | $-109.5M | $-1.2B | ||
| Q2 25 | $-112.1M | $-1.1B | ||
| Q1 25 | $-131.7M | $-1.1B | ||
| Q4 24 | $-109.3M | $-1.0B | ||
| Q3 24 | $-93.4M | $-949.7M | ||
| Q2 24 | $-57.5M | $-756.2M | ||
| Q1 24 | $-63.7M | $-787.2M |
总资产AMRXRXT
| Q4 25 | $3.7B | $2.8B | ||
| Q3 25 | $3.6B | $2.8B | ||
| Q2 25 | $3.4B | $2.9B | ||
| Q1 25 | $3.4B | $3.0B | ||
| Q4 24 | $3.5B | $3.1B | ||
| Q3 24 | $3.5B | $3.1B | ||
| Q2 24 | $3.5B | $3.4B | ||
| Q1 24 | $3.5B | $3.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $59.7M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $56.0M |
| 自由现金流率自由现金流/营收 | 13.3% | 8.2% |
| 资本支出强度资本支出/营收 | 2.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.72× | — |
| 过去12个月自由现金流最近4个季度 | $269.9M | $90.6M |
8季度趋势，按日历期对齐
经营现金流AMRXRXT
| Q4 25 | $130.3M | $59.7M | ||
| Q3 25 | $118.5M | $70.7M | ||
| Q2 25 | $83.8M | $8.4M | ||
| Q1 25 | $7.4M | $12.6M | ||
| Q4 24 | $118.1M | $54.3M | ||
| Q3 24 | $141.8M | $51.8M | ||
| Q2 24 | $39.7M | $24.1M | ||
| Q1 24 | $-4.4M | $-90.3M |
自由现金流AMRXRXT
| Q4 25 | $108.5M | $56.0M | ||
| Q3 25 | $106.2M | $42.7M | ||
| Q2 25 | $61.0M | $-12.4M | ||
| Q1 25 | $-5.8M | $4.3M | ||
| Q4 24 | $102.9M | $34.4M | ||
| Q3 24 | $124.8M | $27.3M | ||
| Q2 24 | $29.0M | $-14.5M | ||
| Q1 24 | $-13.6M | $-118.4M |
自由现金流率AMRXRXT
| Q4 25 | 13.3% | 8.2% | ||
| Q3 25 | 13.5% | 6.4% | ||
| Q2 25 | 8.4% | -1.9% | ||
| Q1 25 | -0.8% | 0.6% | ||
| Q4 24 | 14.1% | 5.0% | ||
| Q3 24 | 17.8% | 4.0% | ||
| Q2 24 | 4.1% | -2.1% | ||
| Q1 24 | -2.1% | -17.1% |
资本支出强度AMRXRXT
| Q4 25 | 2.7% | 0.5% | ||
| Q3 25 | 1.6% | 4.2% | ||
| Q2 25 | 3.2% | 3.1% | ||
| Q1 25 | 1.9% | 1.2% | ||
| Q4 24 | 2.1% | 2.9% | ||
| Q3 24 | 2.4% | 3.6% | ||
| Q2 24 | 1.5% | 5.6% | ||
| Q1 24 | 1.4% | 4.1% |
现金转化率AMRXRXT
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | 0.96× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
RXT
| Public Cloud Services Segment | $442.2M | 65% |
| Private Cloud Service Segment | $240.6M | 35% |
